The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Moving Target: Cardiovascular Risk & Rheumatic Disease

A Moving Target: Cardiovascular Risk & Rheumatic Disease

April 21, 2017 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

With little research and no clear guidelines, physicians have to rely on expert opinions and their own experience when treating patients with both rheumatic and cardiovascular conditions. It’s a significant patient population, treatment is more dynamic and the risk stratification is a moving target, according to rheumatologist and clinical investigator Katherine Liao, MD, of Brigham and Women’s Hospital in Boston.

You Might Also Like
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • Cardiovascular Disease Mortality Risk Remains Higher for Patients with RA
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
Also By This Author
  • Rheumatologists May Not Benefit from Hike in Healthcare Spending

“The relationship between cholesterol, cardiovascular risk and inflammation is different in patients with rheumatic disease. In the general population, higher cholesterol means higher cardiovascular risk. That is not necessarily the case with [our] patients,” says Dr. Liao. “With rheumatic diseases, such as RA [rheumatoid arthritis], we know that treating to general population guidelines is suboptimal. However, we do not yet have data that definitively tell us, ‘yes, if you reduce inflammation, you will reduce cardiovascular risk by X%.’”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Liao says the general population guidelines typically underestimate cardiovascular risk in RA patients by 1.5 to two times. However, the math isn’t that simple.

“The problem is always confounded by the patients’ level of disease activity or inflammation. That can modify what the patients’ risk is,” she notes. “We want to be able to better estimate risk, but we don’t really have a way to do that yet. That is what a lot of studies are looking at.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Liao points out that patients with rheumatic conditions routinely incur inflammation changes, and as a result, changes to lipid levels. Although no validated formula exists, understanding the variance is key, as is knowing when your patient is an outlier due to “flares, length of time the patient has had a rheumatic disease or how much steroid treatment the patient has had.”

When evaluating patients with a C-reactive protein (CRP) test, clinicians should be wary of the results for patients with active rheumatic conditions. In the general population, a CRP result of 3 mg/L is considered elevated and a patient with that result is considered at high risk of heart disease.

“But in RA, you are dealing with a completely different scale,” she says. “The mean CRP in a well-treated RA cohort is about 9 mg/L. If patients are flaring, the CRP easily could be in the 20s or 50s, and it is not unusual to see a level of 100 mg/L. It is a completely different scale of inflammation, and again, we don’t have data on how we should be integrating this information about how we assess [cardiovascular] risk.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: cardiovascular, heart, Rheumatic Disease, rheumatologists

You Might Also Like:
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • Cardiovascular Disease Mortality Risk Remains Higher for Patients with RA
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
  • Cardiovascular Disease Risk High in RA Patients

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)